• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ETHZilla Unveils New Brand Committed to Advancing Ethereum Treasury Strategy

    8/18/25 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNF alert in real time by email

    Company announces new ticker (formally ATNF) and will begin trading on NASDAQ under ETHZ on August 18, 2025

    Company has accumulated 94,675 ETH at an average acquisition price of $3,902.20, which is now valued at approximately $419 million

    PALM BEACH, Fla., Aug. 18, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ), (the "Company" or "ETHZilla"), today announced the official launch of its new brand as part of the Company's transition to focus on its recently announced Ethereum treasury strategy. Previously operating as 180 Life Sciences Corp., ETHZilla will focus a significant portion of its non-legacy operations on becoming an accumulation vehicle for Ether (ETH) that is built for the community, by the community. In addition to the rebrand, the Company's common stock and public warrants will begin trading on The Nasdaq Capital Market under the new ticker symbols "ETHZ" and "ETHZW", as of market open on August 18, 2025, replacing the Company's previous ticker symbols "ATNF" and "ANTFW", respectively. No action is required from stockholders in relation to this change.

    ETHZilla logo (PRNewsfoto/180 Life Sciences Corp.)

    Since the closing of the Company's previously disclosed $425 million private placement of common stock and pre-funded warrants (PIPE) and $156.25 million convertible note offering, the Company has accumulated 94,675 ETH at an average acquisition price of $3,902.20, which is now valued at approximately $419 million. In addition to the ETH, ETHZilla holds approximately $187 million in USD cash equivalents.

    "Today, we are embracing our identity as ETHZilla and our commitment to developing a market-leading strategy that seeks to bring the value of Ethereum to investors in the public markets," said McAndrew Rudisill, Executive Chairman of the Board of Directors of the Company. "We are launching this new brand and our new treasury strategy with significant interest from the market and valuable partnerships with prominent Ethereum ecosystem founders and leaders."

    Successful Private Placement & Convertible Note Expected to Ensure Next Phase of Growth

    The rebrand to ETHZilla follows the successful closing of the Company's private placement and convertible note offering, which raised approximately $565 million in gross proceeds, before placement agent fees and offering expenses (the "Private Placements"). Over 60 institutional and crypto-native investors participated in the PIPE transaction including:

    • Harbour Island;
    • Electric Capital;
    • Polychain Capital;
    • GSR;
    • Borderless Capital;
    • Omicron Technologies;
    • Konstantin Lomashuk (Co-Founder Lido and p2p.org);
    • Sreeram Kannan (Founder, Eigenlayer);
    • Mike Silagadze (Founder, Ether.fi);
    • Danny Ryan (Co-Founder, Etherealize);
    • Vivek Raman (Co-Founder, Etherealize);
    • Sam Kazemanian (Co-Founder, Frax);
    • Grant Hummer (Co-Founder of Etherealize);
    • Robert Leshner (Founder, Compound and Superstate);
    • Tarun Chitra (Founder, Gauntlet);

    and several other prominent Ethereum ecosystem founders and leaders. 

    Capital Deployment Strategy Underway to Begin Significant ETH Accumulation 

    The Company has already begun allocating a significant portion of the net proceeds from the Private Placements for the purchase of ETH, provided the Company continues to support its iGaming operations and is working to monetize its legacy biotech intellectual property assets.

    Electric Capital is serving as the external asset manager for ETHZilla, and plans to implement a differentiated, on-chain yield generation program designed with the goal of outperforming traditional ETH staking, while maintaining robust risk management, to leverage a combination of staking, lending, liquidity provisioning and bespoke private agreements.

    About ETHZilla

    ETHZilla is developing an accumulation vehicle for Ether (ETH), the native digital asset of Ethereum, that aims to become a benchmark for on-chain treasury management among public companies. This strategy will be built for the community, by the community.

    Through its partnership with Electric Capital, ETHZilla's treasury strategy aims to pursue a differentiated yield generation program meant to outperform traditional ETH staking. The Company is supported by an executive team and DeFi Council that unites capital markets experts, prominent Ethereum engineers, top-tier DeFi founders, infrastructure pioneers and other ecosystem heavyweights.

    The Company, originally formed as an innovative biotechnology company, has also been evolving its business towards software enabled gaming and entertainment. In addition to its ETH treasury strategy as discussed above, and its plans to monetize its existing legacy biotech assets, the Company continues to maintain and accelerate the deployment and development of its gaming initiatives.

    Forward Looking Statements

    This press release contains "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected benefits of the Private Placements and related transactions, expectations regarding the capitalization, resources and ownership structure of the Company, the expected benefits of the Company's rebranding, expectations with respect to future performance, and growth of the Company; the ability of the Company to execute its plans, the Company's plans to continue to purchase ETH, the Company's digital asset treasury strategy, the digital assets to be held by the Company, anticipated yield strategies, and future performance. Forward looking statements are subject to numerous risks and uncertainties, many of which are beyond the Company's control, and actual results may differ materially. Applicable risks and uncertainties include, among others, the risk that the proposed transactions described herein may not be completed in a timely manner or at all; failure to realize the anticipated benefits of the PIPE, convertible notes, and related transactions, including the Company's recent digital asset treasury strategy; the Company's ability to achieve profitable operations; fluctuations in the market price of ETH that will impact the Company's accounting and financial reporting; government regulation of cryptocurrencies and online betting; changes in securities laws or regulations; changes in business, market, financial, political and regulatory conditions; risks relating to the Company's outstanding convertible notes, including the Company's ability to repay such notes, covenants associated therewith and dilution caused by the conversion thereof into common stock, and security interests associated therewith; risks relating to the Company's previously announced ATM offering, including potential downward pressure on the Company's stock price associated therewith; risks relating to the Company's operations and business, including the highly volatile nature of the price of Ether and other cryptocurrencies; the risk that the Company's stock price may be highly correlated to the price of the digital assets that it holds; risks related to increased competition in the industries in which the Company does and will operate; risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purpose, expectations with respect to future performance, growth and anticipated acquisitions; potential litigation involving the Company or the validity or enforceability of the intellectual property of the Company; risks relating to the Company's iGaming operations; global economic conditions; geopolitical events and regulatory changes; access to additional financing, and the potential lack of such financing; and the Company's ability to raise funding in the future and the terms of such funding, including dilution caused thereby, as well as those risks and uncertainties identified and those identified under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, as well as the supplemental risk factors and other information the Company has or may file with the SEC, including those disclosed under Item 8.01 of the Current Reports on Form 8-K filed by the Company with the SEC on July 30, 2025 and August 11, 2025. Readers are cautioned not to place undue reliance on these statements. Investors should also be aware that under U.S. generally accepted accounting principles (GAAP), certain crypto assets must be measured at fair value, with changes recognized in net income for each reporting period. These fair value adjustments may cause significant fluctuations in the Company's balance sheet and income statement from period-to-period. In addition, for certain crypto assets, including ETH, which the Company holds, impairment charges may be required to be reported in net income if the market price of such assets (including ETH) falls below the cost basis at which those assets are carried on the balance sheet. Readers are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update any forward-looking statements except as required by law. The Company's business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

    Media Contact:

    Prosek Partners

    pro-ETH@prosek.com 

    Investor Contact:

    Prosek Partners

    [email protected] 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ethzilla-unveils-new-brand-committed-to-advancing-ethereum-treasury-strategy-302531759.html

    SOURCE ETHZilla Corporation

    Get the next $ATNF alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATNF

    DatePrice TargetRatingAnalyst
    9/15/2021$11.00Buy
    Maxim Group
    More analyst ratings

    $ATNF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Woody James N. bought $4,700 worth of shares (25,000 units at $0.19), increasing direct ownership by 60% to 66,888 units (SEC Form 4)

    4 - 180 Life Sciences Corp. (0001690080) (Issuer)

    12/18/23 4:15:16 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    SEC Filings

    View All

    180 Life Sciences Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - ETHZilla Corp (0001690080) (Filer)

    8/20/25 7:30:26 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: 180 Life Sciences Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Leadership Update, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K/A - ETHZilla Corp (0001690080) (Filer)

    8/20/25 7:32:28 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by 180 Life Sciences Corp.

    SCHEDULE 13D/A - ETHZilla Corp (0001690080) (Subject)

    8/18/25 5:22:30 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on 180 Life Sciences Corp. with a new price target

    Maxim Group initiated coverage of 180 Life Sciences Corp. with a rating of Buy and set a new price target of $11.00

    9/15/21 7:48:59 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ATNF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    ETHZilla Unveils New Brand Committed to Advancing Ethereum Treasury Strategy

    Company announces new ticker (formally ATNF) and will begin trading on NASDAQ under ETHZ on August 18, 2025 Company has accumulated 94,675 ETH at an average acquisition price of $3,902.20, which is now valued at approximately $419 million PALM BEACH, Fla., Aug. 18, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ), (the "Company" or "ETHZilla"), today announced the official launch of its new brand as part of the Company's transition to focus on its recently announced Ethereum treasury strategy. Previously operating as 180 Life Sciences Corp., ETHZilla will focus a significant portion of its non-legacy operations on becoming an accumulation vehicle for Ether (ETH) that is built for the

    8/18/25 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences (ETHZilla) Holds 82,186 ETH

    Company Initiates Institutional ETH Accumulation Strategy PALO ALTO, Calif., Aug. 12, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), dba ETHZilla (the "Company", "180 Life Sciences" or "ETHZilla"), announced today that is has total holdings of 82,186 Ether ("ETH") at an average acquisition price of $3,806.71, which is now valued at approximately $349 million. In addition to the ETH, ETHZilla holds approximately $238 million in USD cash equivalents. "At ETHZilla we have put over $350 million in capital to work since the PIPE transaction we completed last week, and

    8/12/25 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Announces Closing of Private Offering of Approximately $156 Million of Convertible Notes

    Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings This milestone follows the announcement of the Company's recently closed $425 million private placement PALO ALTO, Calif., Aug. 11, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), (the "Company" or "ETHZilla"), today announced that it has sold approximately $156 million aggregate principal amount of senior secured convertible notes due 2028 (the "Convertible Notes") in a private offering to an institutional investor on August 8, 2025. The Company intends to us

    8/11/25 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Former 10% Owner Elray Resources, Inc. sold $9,278,586 worth of shares (2,998,000 units at $3.09) and exercised 3,000,000 in-the-money shares at a strike of $1.68, increasing direct ownership by 0.15% to 1,320,000 units (SEC Form 4)

    4 - ETHZilla Corp (0001690080) (Issuer)

    8/18/25 5:27:22 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Executive Chairman Rudisill Mcandrew

    4 - 180 Life Sciences Corp. (0001690080) (Issuer)

    8/12/25 5:20:03 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Heter Crystal Jane

    3 - 180 Life Sciences Corp. (0001690080) (Issuer)

    8/12/25 4:15:12 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 180 Life Sciences Corp.

    SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)

    11/14/24 3:53:30 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by 180 Life Sciences Corp.

    SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)

    10/18/24 5:00:02 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by 180 Life Sciences Corp.

    SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)

    2/14/24 3:27:19 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Leadership Updates

    Live Leadership Updates

    View All

    180 Life Sciences Closes $425 Million Private Placement to Advance its Ethereum Treasury Strategy

    Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings Company plans to execute a differentiated yield generation program, with Company built for the Ethereum community, by the Ethereum community PALO ALTO, Calif., Aug. 4, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), (the "Company" or "ETHZilla"), has closed its previously announced private placement, raising $425 million in gross proceeds, before placement agent fees and offering expenses (the "Private Placement") through a private investment in public equity transaction ("PIPE") for the purchase and sale of common stock and pre-funded warrants, as applicable, at a purchase

    8/4/25 10:30:00 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

    PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr. Stephen Shoemaker as an independent director of the Company and as a member of the Company's audit committee. With this appointment, 180 is now in full compliance with all Nasdaq continued listing requirements and has remedied all previously announced deficiencies.Mr. Blair Jordan, Interim CEO of the Company, stated, "This brings 180 into f

    12/12/24 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors

    PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced the appointment of Stephen Shoemaker to its Board of Directors, effective December 3, 2024.Mr. Shoemaker brings to 180 a wealth of experience as a seasoned senior executive and board member with a diverse background spanning finance, operations management, capital raising, and strategic planning. With over $2 billion in capital raised during his tenure in both CEO and CFO roles across four companies, Mr. Shoemaker has consistently demonstrated his

    12/4/24 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Financials

    Live finance-specific insights

    View All

    180 Life Sciences Corp. - Corporate Updates

    Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance SheetPALO ALTO, CA / ACCESSWIRE / October 3, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180") is pleased to provide a corporate update covering several key initiatives.CORPORATE UPDATE HIGHLIGHTS:Company shifts focus and enters global iGaming market - completes a significant technology acquisitionExpected Compliance with Nasdaq Listing Rule 5550(b)(1) - Company expects to meet Nasdaq continued listing requirement which requires maintenance of stockholders' equity of at least $2.5 millionPositive Study Results on CBD Pill Forms - 180 achieve

    10/3/24 8:30:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care